Marketing: Page 3
-
Oonal via Getty Images
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
By Ned Pagliarulo • Feb. 10, 2025 -
Permission granted by Bristol Myers Squibb
Brain drug revivalBristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
By Jacob Bell • Feb. 6, 2025 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Joe Raedle via Getty Images
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
By Jonathan Gardner • Feb. 4, 2025 -
Justin Sullivan via Getty Images
Judge halts Trump freeze on grants as states report healthcare payment portals back online
States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump administration’s decision to halt federal assistance.
By Rebecca Pifer • Jan. 29, 2025 -
Permission granted by BridgeBio Pharma
Q&ABridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors
In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and Alnylam.
By Ben Fidler • Jan. 23, 2025 -
istockphoto.com/MadamLead
Sponsored by Scientist.comNavigating future biopharma catalysts: What to expect at the 2025 J.P. Morgan Healthcare Conference
The stage is set for JPM 2025—don't miss expert reactions following 2025’s principal catalyst event!
Jan. 6, 2025 -
Stock via Getty Images
GLP-1 drug compounding is in limbo. Will the FDA draw out its decision?
The agency is due to make a determination on the shortage status of Zepbound by Dec. 19. But another delay could be possible and, either way, experts predict more litigation.
By Amy Baxter • Dec. 11, 2024 -
wildpixel via Getty Images
Gene therapy uptake in sickle cell stays slow, despite patient interest
A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.
By Ned Pagliarulo , Gwendolyn Wu • Dec. 9, 2024 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesClinical services organizations are critical to the future of pharma in the APAC market
As APAC contract manufacturing grows, pharma companies turn to outsourcing for cost-effective solutions.
Dec. 9, 2024 -
Scott Olson via Getty Images
Diabetes advocacy group discourages use of compounded GLP-1 drugs
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.
By Jonathan Gardner • Dec. 2, 2024 -
Scott Olson via Getty Images
Biden administration proposes Medicare, Medicaid coverage of pricey weight loss drugs
Millions of Americans who have obesity could gain insurance coverage for drugs like Wegovy if the Trump administration allows the rule to go into effect.
By Rebecca Pifer • Nov. 26, 2024 -
Justin Sullivan via Getty Images
Will Walgreens’ store closures disrupt its clinical trial aims?
Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed to aiding drug research.
By Meagan Parrish • Nov. 22, 2024 -
Courtesy of Merck & Co.
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.
By Jonathan Gardner • Nov. 19, 2024 -
Scott Olson via Getty Images
Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.
By Rebecca Pifer • Nov. 18, 2024 -
Courtesy of Eisai
New Alzheimer's drugsEisai wins over European regulators on Alzheimer’s drug Leqembi
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
By Jacob Bell • Nov. 14, 2024 -
Mario Tama via Getty Images
J&J sues US government for halting 340B rebate plan
The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.
By Rebecca Pifer • Nov. 13, 2024 -
Julia Rendleman via Getty Images
Cigna confirms it is not pursuing Humana acquisition
The formal denial comes after Cigna CEO David Cordani tried to push back on persistent speculation of a Humana merger earlier this fall.
By Rebecca Pifer • Nov. 11, 2024 -
Permission granted by SmartLabs
Sponsored by SmartLabsThinking inside the box: How SmartLabs is driving new collaborations to support the life science industry in global innovation hubs
Seamlessly scale and adapt to match the rapid pace and complexity of modern science.
Nov. 11, 2024 -
Jeenah Moon via Getty Images
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for vaccination with the shot.
By Delilah Alvarado • Oct. 23, 2024 -
Jacob Bell/BioPharma Dive
Amgen plans launch of Eylea biosimilar after court ruling
With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as litigation continues.
By Kristin Jensen • Oct. 23, 2024 -
Courtesy of Novo Nordisk
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
By Jonathan Gardner • Oct. 21, 2024 -
Douglas Cliff via Getty Images
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA has re-opened the door for GLP-1 compounders.
By Amy Baxter • Oct. 21, 2024 -
Justin Sullivan via Getty Images
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
By Jonathan Gardner • Oct. 18, 2024 -
Mario Tama via Getty Images
CVS replaces CEO Karen Lynch with Caremark head
The financially struggling healthcare giant also pulled its earnings guidance, citing increased medical cost pressures in its health benefits unit.
By Emily Olsen • Oct. 18, 2024 -
Mario Tama via Getty Images
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.
By Jonathan Gardner • Oct. 15, 2024
Previous
